• Explore /
  • Poster
  • / A prognostic model for predicting overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) after docetaxel.

A prognostic model for predicting overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) after docetaxel.

Abstract Poster

Authors

null

Kim N. Chi

British Columbia Cancer Agency, Vancouver, BC, Canada

Kim N. Chi , Thian San Kheoh , Charles J. Ryan , Arturo Molina , Joaquim Bellmunt , Nicholas J. Vogelzang , Dana E. Rathkopf , Karim Fizazi , Philip W. Kantoff , Jinhui Li , Johann Sebastian De Bono , Howard I. Scher

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Genitourinary (Prostate) Cancer

Track

Genitourinary Cancer

Sub Track

Prostate Cancer

Clinical Trial Registration Number

NCT00638690

Citation

J Clin Oncol 31, 2013 (suppl; abstr 5013)

DOI

10.1200/jco.2013.31.15_suppl.5013

Abstract #

5013

Poster Bd #

5

Abstract Disclosures

Similar Posters

First Author: Gregory Russell Pond

First Author: Shingo Hatakeyama

First Author: Celestia S. Higano

First Author: Rebeca Lozano